Yeast; Media Therefor Patents (Class 435/254.2)
  • Patent number: 12234465
    Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as isobutanol are disclosed. For example, genetically modified methanotrophs that are capable of generating isobutanol at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: February 25, 2025
    Assignee: PRECIGEN, INC.
    Inventors: Jeffrey David Orth, Louis A. Clark, Lily Yuin Chao, Na My Trinh, Christopher Cheyney Farwell, Xinhua Zhao, Matthias Helmut Schmalisch, Grayson Thomas Wawrzyn, Xuezhi Li, Mark Anton Held, Kevin Lee Dietzel, James Kealey
  • Patent number: 12234261
    Abstract: Provided herein are engineered hepatitis B virus (HBV) molecular vaccine constructs. Vaccine constructs can also include ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as a cytokines, in host cells.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: February 25, 2025
    Assignee: Precigen, Inc.
    Inventors: Douglas E. Brough, Cheryl G. Bolinger, Ramya Yarlagadda, Vinodhbabu Kurella, Prabakaran Ponraj, Simon Metenou, Kuan-Fu Ding
  • Patent number: 12234495
    Abstract: The biological production of beta-hydroxyisovalerate (?HIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived ?HIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active ?HIV metabolic pathway for the production of ?HIV. Alternatively, the non-natural enzyme can be a ?HIV synthase used to produce ?HIV in a cell-free environment. The biological derivation of ?HIV eliminates toxic by-products and impurities that result from the chemical production of ?HIV, such that ?HIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: February 25, 2025
    Assignee: Sasya Inc.
    Inventors: Goutham Vemuri, Christopher Lindsay, Kevin Roberg-Perez, Christopher D. Snow, Elizabeth A. Cameron
  • Patent number: 12220461
    Abstract: A polypeptide-coupled small molecule compound and its antiviral applications are provided. The polypeptide-coupled small molecule compound is obtained by linking a polypeptide with a sequence X?nLXGG and a small molecule compound capable of inhibiting activity of papain-like protease (PLpro) of coronavirus through a chemical bond. The polypeptide with the sequence X?nLXGG is a polypeptide with a sequence LXGG at its carboxyl terminal, X and X? are independently any amino acid, and n is an integer between 1-50. The structure of the small molecule compound capable of inhibiting the activity of PLpro contains an amino group or a hydroxyl group. The polypeptide-coupled small molecule compound can inhibit the PLpro of SARS-CoV-2 in a targeted manner, thereby inhibiting the polyprotein cleavage of coronavirus in the host, and achieving the purpose of inhibiting the replication of coronavirus in the host. It has the advantages of synergistic inhibition, low cytotoxicity and favorable solubility.
    Type: Grant
    Filed: May 17, 2024
    Date of Patent: February 11, 2025
    Assignee: Guangzhou Medical University
    Inventors: Xiyong Yu, Ao Shen, Hua Tao, Lixin Zhao, Nanshan Zhong, Qiulian Zhu
  • Patent number: 12214085
    Abstract: Nanoparticles and formulations for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are disclosed. The nanoparticles contain a cage, such as a zeolitic imidazolate framework (“ZIF”), a surface modifying agent, a targeting ligand, and an active agent. The surface modifying agent is attached to the outer surface of the cage and the targeting ligand is exposed to the surrounding environment. The active agent is encapsulated in the cage. The targeting ligand binds to a reproductive hormone or a receptor of a reproductive hormone. The active agent can be a ribosome inactivating protein, an apoptosis inducer, a hormone, a receptor ligand, or a nucleic acid, or a combination thereof, that inactivate ribosomes of gonadotroph cells and/or prevent or reduce secretion of follicle-stimulating hormones in the subject. Uses for formulations incorporating the nanoparticles for preventing or reducing peri-/post-menopausal bone loss and/or obesity in a subject are also disclosed.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: February 4, 2025
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Sheba M. J. MohanKumar, Puliyur S. MohanKumar, Yen-Jun Chuang
  • Patent number: 12209127
    Abstract: Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1 and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: January 28, 2025
    Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
    Inventors: Samir Khleif, Mikayel Mkrtichyan
  • Patent number: 12203143
    Abstract: The present invention provides a method of detecting one or more Klebsiella species within a sample from a subject, the method comprising: subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting species-specific canonical single nucleotide polymorphisms (canSNPs); and analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Klebsiella species. The present invention also provides a kit for detection of one or more Klebsiella species, Klebsiella clonal groups, AMR genes, and/or virulence genes, the kit comprising primer pairs targeting species-specific canSNPs, K. pneumoniae genes M1 and M2, clonal group-specific canSNPs, AMR genes, and/or virulence genes.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: January 21, 2025
    Assignees: The Translational Genomics Research Institute, Arizona Board of Regents on behalf of Northern Arizona University
    Inventors: Jolene Bowers, Elizabeth Driebe, David Engelthaler, Paul Keim, Darrin Lemmer
  • Patent number: 12203076
    Abstract: The present invention relates to a method for introducing mutations into at least one target nucleic acid molecule comprising (a) providing at least one sample comprising at least one target nucleic acid molecule; and (b) amplifying the at least one target nucleic acid molecule using a low bias DNA polymerase. The present further relates to a use of a low bias DNA polymerase in a method for introducing mutations into one or more nucleic acid molecule(s), a group of sample tags, a method for designing the group of sample tags, a computer readable medium, and a method for preferentially amplifying target nucleic acid molecules.
    Type: Grant
    Filed: June 20, 2022
    Date of Patent: January 21, 2025
    Assignee: Illumina Singapore Pte. Ltd.
    Inventors: Leigh G. Monahan, Joyce To, Catherine Maree Burke, Michael Imelfort, Aaron Earl Darling
  • Patent number: 12195529
    Abstract: The invention provides bispecific heterodimeric antibodies with modified heavy chain IgG constant regions that promote efficient assembly of antibody heavy chain heterodimer pairs, as well as arm specific pairing of heavy and light chains.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 14, 2025
    Assignee: GSBIO, LLC
    Inventor: Guriqbal S. Basi
  • Patent number: 12186376
    Abstract: The present invention is related to a method of treating or preventing cancer in a subject comprising administering to a subject having cancer or prone of getting cancer a first agent that depletes the subject's regulatory T cells (Tregs); followed by administering to the subject a second agent comprising a checkpoint inhibitor.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: January 7, 2025
    Assignee: The Johns Hopkins University
    Inventors: William R. Bishai, John R. Murphy, Drew M. Pardoll, Laurene Cheung, Juan Fu, Pankaj Kumar, Amit Kumar, Sadiya Parveen, Cynthia Korin Bullen, Vijayan Sambasivam, Sumit Siddharth, Dipali Sharma
  • Patent number: 12171821
    Abstract: Methods of preparing mammalian enteroids, and methods producing T. gondii oocysts in vitro and in vivo in heterologous systems, are provided.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: December 24, 2024
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Laura Knoll, Bruno Martorelli Di Genova
  • Patent number: 12157902
    Abstract: Disclosed are a recombinant acid-resistant yeast having lactic acid-producing ability and suppressed glycerol production and a method of preparing lactic acid using the same. More particularly, disclosed are a recombinant acid-resistant yeast into which a gene involved in lactic acid production is introduced and in which a gene involved in glycerol production is deleted or attenuated, and a method of preparing lactic acid using the same. When producing lactic acid using the recombinant acid-resistant yeast, the production of lactic acid is maintained while the production of glycerol is reduced, so crosslinking by glycerol can be suppressed in the oligomerization reaction for conversion to lactide, and thus the conversion yield of lactic acid to lactide can be increased.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: December 3, 2024
    Assignee: SK Innovation Co., Ltd.
    Inventors: Jae Yeon Park, Ki Sung Lee, Tae Young Lee
  • Patent number: 12152079
    Abstract: Some embodiments of the methods and compositions provided herein relate to chimeric antigen receptors (CARs) that specifically bind to human extracellular domains of the IL-13 alpha 2 (IL13Ra2) receptor, cells containing such CARs, and methods of cell-based immunotherapy targeting cancer cells, such as cells of solid tumors.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: November 26, 2024
    Assignee: Seattle Children's Research Institute
    Inventors: Giacomo Tampella, Michael C. Jensen
  • Patent number: 12152059
    Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO: 1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: November 26, 2024
    Assignee: TASLY BIOPHARMACEUTICALS CO., LTD.
    Inventors: Jian Li, Jun Han, Xiaohui Ma, Ping Tai, Genbei Wang, Xiaodan Cao, Ruijing Huang, Yongjie Jin, Jing Li, Chen Chen, Guoyong Jia, Yuanyuan Wang
  • Patent number: 12146157
    Abstract: Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer, such as PTK7+ malignancies.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: November 19, 2024
    Inventors: Jonathan Alexander Terrett, Jason Sagert
  • Patent number: 12139552
    Abstract: Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 17th, 18th and 20th amino acid residues of a light chain defined by Kabat method to charged amino acid residues.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: November 12, 2024
    Assignee: SYSMEX CORPORATION
    Inventors: Shingo Maeta, Atsushi Fukunaga, Reema Bajaj
  • Patent number: 12134638
    Abstract: SIRPalpha-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a SIRPalpha variant. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-41BBL fusion protein or the isolated polypeptide, host-cells expressing same and methods of use thereof.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: November 5, 2024
    Assignee: KAHR Medical Ltd.
    Inventors: Iris Pecker, Itai Bloch
  • Patent number: 12134794
    Abstract: Provided herein are microorganisms and methods for fermentative production of ?-ketoadipate from gaseous substrates such as carbon dioxide (CO2), carbon monoxide (CO), and/or hydrogen (H2). Additionally, the processes provided herein are methods for producing polymers containing ?-ketoadipate, that can potentially enable a circular economy by diverting waste, e.g., plastic waste.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: November 5, 2024
    Assignee: LanzaTech, Inc.
    Inventors: James Daniell, Michael Koepke, Rasmus Overgaard Jensen
  • Patent number: 12129506
    Abstract: This invention relates to metabolically engineered microorganism strains, such as bacterial strains, in which there is an increased utilization of malonyl-CoA for production of a fatty acid or fatty acid derived product, wherein the modified microorganism produces fatty acyl-CoA intermediates via a malonyl-CoA dependent but malonyl-ACP independent mechanism.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: October 29, 2024
    Assignee: CARGILL, INCORPORATED
    Inventors: Michael D. Lynch, Michael Tai Man Louie, Shelley Copley, Eileen Colie Spindler, Brittany Robinson, Matthew Lipscomb, Tanya Lipscomb-Warnecke, Hans H. Liao, David Hogsett, Ron Evans
  • Patent number: 12129297
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: October 29, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Yu-Cheng Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
  • Patent number: 12129296
    Abstract: Provided are an anti-human claudin 18.2 monoclonal antibody and application thereof. The antibody has three heavy chain CDRs and three light chain CDRs, one of the three heavy chain CDRs and three light chain CDRs is as follows: a heavy chain CDR1 is SEQ ID NO: 1, a heavy chain CDR2 is SEQ ID NO: 2, a heavy chain CDR3 is SEQ ID NO: 3, a light chain CDR1 is SEQ ID NO: 4, a light chain CDR2 is SEQ ID NO: 5, and a light chain CDR3 is SEQ ID NO: 6.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: October 29, 2024
    Assignee: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD
    Inventors: Yanyan Wu, Wenjun Cui, Chenfei Hu
  • Patent number: 12123049
    Abstract: The present invention relates to methods and systems for cell lysis in a microfluidic device. More specifically, embodiments of the present invention relate to methods and systems for rapid continuous flow pathogen cell lysis. In one embodiment, the microfluidic device comprises a microfluidic channel, a microporous structure within the channel, and an enzyme immobilized on the surface of the microporous structure configured to lyse pathogen cells in fluid flowing through the microfluidic channel.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: October 22, 2024
    Assignee: University of Maryland
    Inventors: Ian M White, Stephen Restaino, Marina Pranda
  • Patent number: 12099783
    Abstract: A computer-implemented method is provided for simulating sensor data acquisition. The method may include receiving simulated sensor data corresponding with a synthetic object in a simulated three-dimensional (3D) environment. The method may also include identifying an object type corresponding with the synthetic object based on a location of the synthetic object in the simulated 3D environment. The method may further include associating an intensity value with the simulated sensor data based on the object type for the synthetic object.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: September 24, 2024
    Assignee: GM Cruise Holdings LLC
    Inventors: Richard Stenson, Joel Gross
  • Patent number: 12054524
    Abstract: The present inventors confirmed that when a brazzein expression recombinant vector for high expression of brazzein in Saccharomyces cerevisiae was prepared and a S. cerevisiae strain Y2805 was transformed with the recombinant vector, the expression level of brazzein was particularly high, thereby completing an optimal expression system for mass-producing brazzein. Further, when the brazzein expression system is cultured under the optimal culture conditions according to the present invention, the amount of brazzein produced is further increased, the purification process is simple, and costs are reduced. Therefore, it is expected that the brazzein expression system according to the present invention can be widely used for mass-producing and commercializing brazzein, which is a sweet protein.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: August 6, 2024
    Assignee: CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Kwang Hoon Kong, Han Seul Kim, Si Wook Jang, Gi Hyeon Chae
  • Patent number: 12054721
    Abstract: The present application discloses genetically modified yeast cells comprising an active 3-HP fermentation pathway, and the use of these cells to produce 3-HP.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: August 6, 2024
    Assignee: CARGILL, INCORPORATED
    Inventors: Holly Jessen, Brian Rush, Jeanette Huryta, Beth Mastel, Alan Berry, Debbie Yaver, Michael Catlett, Michelle Barnhart
  • Patent number: 12039461
    Abstract: A method for inducing a covert misclassification performed on a non-transitory computer readable medium, the method includes identifying a target position. The method further includes creating a spectral perturbation tensor. The spectral perturbation tensor is configured to shift a projection of an initial spectrum towards the target position. Additionally, the method includes combining the spectral perturbation tensor to the initial spectrum. Further, the method includes classifying the combination of the spectral perturbation tensor and the initial spectrum with an established classifier, thereby designing the spectral perturbation tensor such that the combination is misclassified.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: July 16, 2024
    Assignee: Purdue Research Foundation
    Inventors: Garth Jason Simpson, James Ulcickas, Casey Smith, Alex Sherman
  • Patent number: 11999941
    Abstract: The present invention relates to a composition comprising at least one carrier comprising a polysaccharide, at least one antioxidant and at least one amino acid selected from cysteine, lysine, alanine and arginine. It also relates to the use of such a composition for the protection of microorganisms during drying, storage and/or reconstitution, to a culture powder, to a process of making the culture powder and to products comprising the culture powder.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: June 4, 2024
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Edwin Ananta, Biljana Bogicevic, Carsten Cramer, Alexandra Dubois, Judith Gaulocher, Katja Johnson, Jeroen Andre Muller, Matthias Perren, Guenolee Eliane Marie Prioult, Sabine Sres, Wilbert Sybesma
  • Patent number: 11976381
    Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: May 7, 2024
    Assignee: BioAtla, Inc.
    Inventor: Jay Milton Short
  • Patent number: 11965034
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: April 23, 2024
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerlinde Wernig, Irving L. Weissman
  • Patent number: 11965030
    Abstract: Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: April 23, 2024
    Assignee: SANOFI
    Inventors: Marta Amaral, Christian Beil, Ingo Focken, Gerhard Hessler, Soraya Hoelper, Jennifer Jung, Christian Lange, Wulf-Dirk Leuschner, Ercole Rao, Garima Tiwari, Sandra Weil
  • Patent number: 11965201
    Abstract: The invention provides methods for improving efficiency of fermentation by arginine supplementation, and genetically modified bacterium for use therefor. More particularly the invention provides methods for (i) increasing the production ATP intensive products with arginine supplementation, (ii) increasing utilization of arginine by a C1-fixing bacterium; and (iii) providing C1-fixing bacterium with optimized arginine de-aminase pathways.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: April 23, 2024
    Assignee: LanzaTech NZ, Inc.
    Inventors: Kaspar Valgepea, Michael Koepke, James Bruce Yarnton Haycock Behrendorff, Esteban Marcellin, Lars K. Nielsen, Renato de S. P. Lemgruber
  • Patent number: 11959069
    Abstract: The invention relates to a method for separating a polynucleotide insert from a polynucleotide vector backbone. The backbone has a plurality of cleavage sites distributed such that the backbone is converted into fragments when the sites are cleaved. This allows straightforward separation of the insert from the backbone. The invention also relates to backbones for use in such a method, and to plasmids and kits comprising such backbones.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: April 16, 2024
    Assignee: ProteoNic Biotechnology IP B.V.
    Inventors: Bart Marinus Engels, Raymond Michael Dimphena Verhaert, Maurice Wilhelmus Van der Heijden
  • Patent number: 11952577
    Abstract: Provided herein compositions and methods for producing isoprenoids, including squalene. In certain aspects and embodiments provided are genetically converted yeast and uses therefore. In some aspects and embodiments, the genetically converted yeast produce isoprenoids, preferably squalene. Also are provided methods of producing squalene using a genetically converted yeast or a non-genetically converted yeast. The invention also provides squalene produced by genetically converted yeast or non-genetically converted yeast.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: April 9, 2024
    Assignee: NUCELIS LLC
    Inventors: Keith A. Walker, Mark E. Knuth, Noel M. Fong, Peter R. Beetham
  • Patent number: 11945847
    Abstract: The present disclosure relates to compounds, compositions, and methods for the inducing neurodegenerative disease pathologies. In one aspect, disclosed herein is a nucleotide sequence encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a neurodegenerative disease in target protein. Disclosed herein is a method of inducing a neurodegenerative disease pathology in a cell, comprising the steps: introducing into the cell an expression vector encoding a chimeric polypeptide, comprising: a first nucleotide sequence encoding a light-induced oligomerization domain and a second nucleotide sequence encoding a low complexity domain from a neurodegenerative disease target protein, wherein the first nucleotide sequence is operably linked to a promoter; expressing the chimeric polypeptide; and inducing oligomerization of the chimeric polypeptide by stimulation with blue light.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: April 2, 2024
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Christopher James Donnelly, Jacob R. Mann
  • Patent number: 11939602
    Abstract: The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds.
    Type: Grant
    Filed: November 30, 2022
    Date of Patent: March 26, 2024
    Inventors: Ish K. Dhawan, Gregory Miller, Xiyun Zhang
  • Patent number: 11926850
    Abstract: The present invention relates to genetically modified yeasts that can use lactate as a carbon source to produce a fermentation product. In one aspect, the yeasts can consume glucose and lactate simultaneously to produce ethanol. In one aspect, the genetically modified yeast is transformed to include a monocarboxylic/monocarboxylate transporter. In one aspect, the yeast can include one or more heterologous genes encoding lactate dehydrogenase (cytochrome) (EC 1.1.2.3 and/or 1.1.2.4).
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: March 12, 2024
    Assignee: CARGILL, INCORPORATED
    Inventors: Arlene M. Fosmer, Christopher K. Miller, Gregory Michael Poynter, Brian Jeffrey Rush, Jon Veldhouse
  • Patent number: 11926856
    Abstract: The present invention relates to isolated polypeptides having D-psicose 3-epimerase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Novozymes A/S
    Inventors: Xinyu Shen, Randall Scott Deinhammer, James Ron Huffman, Kendra Stallings, Tine Hoff, Jesper Salomon, Anne Goldbech Olsen
  • Patent number: 11913044
    Abstract: Some aspects of this disclosure relate to strategies, systems, methods, compositions, and kits that are useful for production (e.g., evolution) of cytidine deaminase protein variants that are characterized by increased soluble expression and/or stability relative to the wild-type cytidine deaminase protein from which they are evolved. In some embodiments, evolved cytidine deaminase variants described by the disclosure are useful for incorporation into targeted nucleic acid editing proteins, for example in fusion proteins with a Cas9 domain or variant thereof.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 27, 2024
    Assignees: President and Fellows of Harvard College, The Broad Institute, Inc.
    Inventors: David R. Liu, Tina Wang
  • Patent number: 11905517
    Abstract: The invention relates to recombinant Kluyveromyces lactis (K. lactis) yeasts which are capable of the highly efficient expression of one or more foreign proteins and are suitable for use as a vaccine for generating a protective immune response against pathogens. The invention provides in particular K. lactis strains for the targeted cloning of foreign antigen-coding nucleic acids into the yeast genome of the K. lactis strain, which is characterized in that the K. lactis strain has integrated expression cassettes for foreign antigens as an alternative or in addition to the KILAC4 locus on the KIURA3-20 locus (KLLA0E22771g) and/or on the KIMET5-1 locus (KLLA0B03938g). The invention further relates to integrative expression vectors and to methods for producing the K. lactis strains of the invention as well as to the use thereof as vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 20, 2024
    Assignee: VEROVACCINES GMBH
    Inventors: Hans Caspar Hührlimann, Martina Behrens, Mandy Gebauer, Karin Breunig, Sven-Erik Behrens
  • Patent number: 11884741
    Abstract: Disclosed is a method for producing a modified antibody, comprising: in a heavy chain of the antibody, changing at least one amino acid residue selected from the group consisting of 8th to 11th amino acid residues based on Kabat method to a cysteine residue, and changing at least one amino acid residue selected from the group consisting of 109th and 110th amino acid residues based on IMGT method to a cysteine residue; and recovering the modified antibody.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: January 30, 2024
    Assignee: SYSMEX CORPORATION
    Inventors: Tomofumi Nakada, Nobuyuki Ide
  • Patent number: 11873510
    Abstract: This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: January 16, 2024
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventor: Bellur Prabhakar
  • Patent number: 11851684
    Abstract: Disclosed is an expression cassette comprising, in a 5? to 3? direction of a sense strand, a promoter, and a first nucleic acid, a terminator and a second nucleic acid operably linked to the promoter, wherein the first nucleic acid and the second nucleic acid each contain at least one gene.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 26, 2023
    Assignee: Spiber Inc.
    Inventor: Masahiro Murakami
  • Patent number: 11851694
    Abstract: The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 26, 2023
    Assignee: ModernaTX, Inc.
    Inventors: David Mauger, Vladimir Presnyak, Amy E. Rabideau, Iain Mcfadyen
  • Patent number: 11845799
    Abstract: Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 19, 2023
    Assignee: Genentech, Inc.
    Inventors: WeiYu Lin, Christoph Spiess, Liping Sun, Yan Wu, Cecilia P. C. Chiu, Walter Christian Darbonne, Michael Andrew Dillon
  • Patent number: 11834483
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: December 5, 2023
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jared Lopes, Heather C. Losey, Raymond J. Winquist
  • Patent number: 11827677
    Abstract: The present invention provides an antimicrobial peptide ID13 (with a sequence set forth in SEQ ID NO. 1), a preparation method and use thereof. The antimicrobial peptide ID3 is successfully expressed in Pichia pastoris using genetic engineering technology. The antimicrobial peptide ID13 of the present invention has an excellent bactericidal activity against Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus suis, and has a low hemolytic activity against mouse red blood cells and a low murine macrophage cytotoxicity.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: November 28, 2023
    Assignee: Feed Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Jianhua Wang, Bing Li, Da Teng, Ruoyu Mao, Xiumin Wang, Ya Hao, Na Yang
  • Patent number: 11827908
    Abstract: A novel luciferase with a small molecular weight is provided. A polypeptide with luciferase activity comprising an amino acid sequence (A) or (B) is provided: (A) an amino acid sequence as set forth in SEQ ID NO: 1 with deletion of amino acid residues at positions 1 to 69 and 204 to 221; or (B) an amino acid sequence as set forth in SEQ ID NO: 1 with deletion of amino acid residues at positions 1 to 69 and deletion or substitution of at least one of amino acid residues 146 to 156.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: November 28, 2023
    Assignee: SHIMADZU CORPORATION
    Inventor: Yuki Ohmuro
  • Patent number: 11821001
    Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: November 21, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Wei Xue, John Chen, Carolyn Scott, Theodore Loney, Nathaniel Golden
  • Patent number: 11819525
    Abstract: The present invention relates to an animal feed or an animal feed additive comprising Bacillus strains which improve the health and performance of production animals, and the use of such.
    Type: Grant
    Filed: September 20, 2022
    Date of Patent: November 21, 2023
    Assignee: Novozymes A/S
    Inventors: Adam Nelson, Erik Eckhardt, Estelle Devillard, Meagan Hale, Emily Zhang, Ethan Chad Baker
  • Patent number: 11802274
    Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: October 31, 2023
    Assignee: Codexis, Inc.
    Inventors: Oscar Alvizo, Melissa Ann Mayo, Jeffrey C. Moore